3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
4
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
42
Carcinoma, Non-Small-Cell Lung
18
Neoplasms
15
Neoplasm Metastasis
14
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
8
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Uveal Melanoma
5
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Mesothelioma
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma, Transitional Cell
5
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Lung Neoplasms
4
Carcinoma, Merkel Cell
4
Advanced Cancer
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Liver Neoplasms
3
Hodgkin Disease
3
Head and Neck Neoplasms
3
Carcinoma
3
Interventions
Oxaliplatin
16
Irinotecan
12
Fluorouracil
12
Leucovorin
10
Bevacizumab
8
pembrolizumab
7
Cetuximab
7
Capecitabine
7
Nivolumab
5
Gemcitabine
5
Cyclophosphamide
5
fludarabine
4
aldesleukin
4
Panitumumab
4
Folfox protocol
4
oblimersen
3
Interleukin-2
3
selpercatinib
2
poly ICLC
2
labetuzumab
2
dehydroftorafur
2
conatumumab
2
cemiplimab
2
bintrafusp alfa protein, human
2
Tomography, X-Ray Computed
2
Specimen Handling
2
Receptor Protein-Tyrosine Kinases
2
Radiotherapy
2
Levoleucovorin
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colonic Neoplasms
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts